Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis.
CAS Number:
[339308-60-0]
Target:
IL Receptor/Related
* VAT and and shipping costs not included. Errors and price changes excepted